Skip to main content
ARS Home » Northeast Area » Boston, Massachusetts » Jean Mayer Human Nutrition Research Center On Aging » Research » Publications at this Location » Publication #386339

Research Project: Energy Met.: Novel Approaches to Facilitating Successful Energy Regulation in Aging--Obesity & Met.: Role of Adipocyte Metabolism in the Development of Obesity and Associated Metabolic Complications

Location: Jean Mayer Human Nutrition Research Center On Aging

Title: Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trial

Author
item DORLING, JAMES - Pennington Biomedical Research Center
item RAVUSSIN, ERIC - Pennington Biomedical Research Center
item REDMAN, LEANNE - Pennington Biomedical Research Center
item BHAPKAR, MANJUSHRI - Duke University School Of Medicine
item HUFFMAN, KIM - Duke University School Of Medicine
item RACETTE, SUSAN - Washington University School Of Medicine
item DAS, SAI KRUPA - Jean Mayer Human Nutrition Research Center On Aging At Tufts University
item APOLZAN, JOHN - Pennington Biomedical Research Center
item KRAUS, WILLIAM - Duke University School Of Medicine
item HOCHSMANN, CHRISTOPH - Pennington Biomedical Research Center
item MARTIN, CORBY - Pennington Biomedical Research Center

Submitted to: European Journal of Nutrition
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 8/5/2020
Publication Date: 8/14/2020
Citation: Dorling, J.L., Ravussin, E., Redman, L.M., Bhapkar, M., Huffman, K.M., Racette, S.B., Das, S.W., Apolzan, J.W., Kraus, W.E., Hochsmann, C., Martin, C.K. 2020. Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trial. European Journal of Nutrition. https://doi.org/10.1007/s00394-020-02361-7.
DOI: https://doi.org/10.1007/s00394-020-02361-7

Interpretive Summary: Calorie restriction (CR), defined as a reduction in caloric intake while maintaining nutrition, is an effective treatment for obesity-related liver and metabolic disease. However, further research is needed to determine whether calorie restriction can delay the onset of disease in individuals without obesity. Specific biomarkers, or measurable biological features that indicate the presence or progress of disease, can be used to determine liver health and are linked with cardiometabolic disease. We examined the effects of a two-year calorie restriction program-known as the Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) study-on five liver biomarkers in healthy individuals without obesity. Of the 218 study participants, 143 were randomly assigned to a calorie restriction group (aimed to consume 25% less calories than required) and 75 were randomly assigned to a control group (allowed to consume calories without restraint). In metabolically healthy individuals without obesity, two years of moderate calorie restriction improved several liver biomarkers, with potentially greater improvements in men. Our findings suggest that sustained calorie restriction may improve long-term liver and metabolic disease risk in healthy adults without obesity.

Technical Abstract: Purpose: Calorie restriction (CR) is an effective treatment for obesity-related liver and metabolic disease. However, CR studies in individuals without obesity are needed to see if CR could delay disease onset. Liver biomarkers indicate hepatic health and are linked to cardiometabolic disease. Our aim was to examine the effects of a 2-year CR intervention on liver biomarkers in healthy individuals without obesity. Methods: The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) study was a 2-year randomized controlled trial. Overall, 218 participants (body mass index: 25.1 +/-1.7 kg/m2) were enrolled into a control group (n=75) that ate ad libitum (AL), or a CR group (n=143) that aimed to decrease energy intake by 25%. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin were measured during the trial. Results: At month 24, relative to the AL group, ALP (-7 +/-1 IU/L; P<0.01) and GGT (-0.11 +/-0.04 log IU/L; P=0.02) decreased and bilirubin increased (0.21 +/-0.06 log mg/dL; P<0.01) in the CR group; no between-group differences in ALT (-1 +/-1 IU/L; P>0.99) or AST (2 +/-2 IU/L; P=0.68) were revealed. However, sex-by-treatment-by-time interactions (P<0.01) were observed, with CR (vs. control) inducing reduced ALT and GGT and increased AST in men only (P